News and Updates

Pfizer’s lung cancer drug trial, acquired from the Seagen deal, has failed to meet key goals. Read the latest on the clinical trial results and future impact.

A major NSCLC clinical trial shows sigvotatug vedotin failed to improve overall survival. Read the analysis of these trial results and future implications.

Discover how Operation Trailblazer is revolutionizing CDMO operations and CMC strategies to drive efficiency and regulatory excellence in drug manufacturing.

HHS has launched a major reform drive to streamline clinical trials, aiming to boost US biotech innovation and compete with growing global rivals.

HHS has deployed an experimental drug for clinical testing to combat Ebola. Learn how this trial aims to improve survival rates and global outbreak response.

Autonomous AI is hitting milestones in diagnostic accuracy, but experts warn that integrating these tools into clinical practice remains the real hurdle.

Silexion Therapeutics wins German regulatory approval to start a Phase 2b trial for its innovative KRAS-targeting RNA cancer therapy. Learn more here.

Pfizer's Phase 3 trial for a key Seagen-acquired ADC fails to meet primary endpoints in NSCLC patients, impacting the company's oncology pipeline strategy.

GondolaBio reports successful Phase IIa trial results for PORT-77, showing strong safety data and promising efficacy in treating inflammatory conditions.

The FDA has approved Phase I clinical trials for ASC35, a monthly GLP-1R/GIPR dual agonist aimed at revolutionizing obesity treatment via long-acting dosing.